Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4523MR)

This product GTTS-WQ4523MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4523MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15880MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ15603MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ8571MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ14899MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ1725MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ8259MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ11576MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ14050MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aLAG367
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW